Neeva Brings Responsible, Citation-Backed AI Powered Search to Europe
13.2.2023 14:00:00 EET | Business Wire | Press release
Advert and tracker-free search engine Neeva has today launched NeevaAI in Europe, which harnesses the power of artificial intelligence (AI) to deliver an experience that combines the best of large language models such as ChatGPT with the authority and timeliness of search.
Following a successful beta launch in the US in December 2022, NeevaAI is available to Free Basic and Premium users across the world from today. NeevaAI will be launching its English Language version in the UK and Canada, as well as local language versions in Germany, France and Spain.
NeevaAI provides a synthesised single answer with linked sources pulled together from the most relevant sites for a query, allowing users to determine the authenticity and reliability of the cited sources. The feature offers current information by crawling hundreds of millions of pages a day and serving from its independent index of billions of pages. By combining AI with Neeva's in-house search stack that eschews ads and advertisers, results are fast, timely, bias-free and relevant.
Real-time summaries backed by sources
Unlike other AI search offerings, NeevaAI offers current information to the user by interrogating a page, understanding its contents and incoming links to determine whether the page is useful and authoritative and cite the information source. NeevaAI does this in real time as the web changes, which is vital in our fast paced world.
In a feature unique to Neeva, NeevaAI also provides citation cards, in which a search query returns a visual search result with machine learning summaries from all the top results and swipeable cards highlighting authoritative information about the researched topic. The cards also suggest important research questions for the searcher.
Neeva Founder and CEO, Sridhar Ramaswamy comments: “AI is already beginning to make search one of the first and most clearly disrupted industries. NeevaAI leverages in-house LLMs and refined training models with its full system search stack to bring authentic real time AI search to the everyones. Our goal has been to responsibly integrate AI and provide authoritative answers that you can trust.”
Support for publishers in a post-ChatGPT world
Publishers and content creators stand to be greatly impacted by certain AI search models. AI will fundamentally shift individuals’ relationship to finding and consuming information. For publishers, this should be canary in the coal mine, and failing to adapt to this new reality could prove catastrophic for their businesses.
Nowhere is the threat more immediate than in search. As search engines become answer engines, publisher content will get sucked into the AI bots and served back to users without attribution or links. Without links embedded in the AI answer, users won’t find their way to a publisher’s website, effectively choking off the referral traffic pipeline. Significant drops in referral traffic will lead to material impacts on ad revenue especially at a time when most publishers are fighting just to stay afloat. To make matters worse, that same content will also be used to further train large language models (LLMs) exacerbating the publisher’s dilemma.
Neeva is committed to helping publishers leverage AI and LLMs to re-take ownership of the relationships with their users. Neeva is working to help publishers integrate fluent AI search natively in their websites allowing users to discover and consume content seamlessly. Moreover, to support publishers, whose referral traffic is now at greater risk from AI answer bots, Neeva has committed 20% of its topline revenue to content creator and publisher partners when their content is used to directly answer a Neeva customer’s query.
Since launching in the US in 2021, and Europe in late 2022, Neeva has amassed nearly 2 million users. It has built one of the largest independent search stacks crawling hundreds of millions of pages a day and an index of billions. By combining AI with Neeva’s in-house search stack, NeevaAI’s results are lightning fast, timely, and relevant.
ENDS
About Neeva
Neeva is the world’s first ads-free, private subscription search engine powered by AI. Neeva focuses entirely on the consumer, delivering only real, high quality, trustworthy results. Neeva is leading a new AI frontier by leveraging in-house LLMs and refined training models with our full system search stack to bring authentic real-time AI search to everyone. Neeva blocks third-party website trackers, and will never sell or share customer data with anyone, especially advertisers. Neeva also makes it easy to search within personal email accounts, calendars, and cloud storage platforms surfacing the most important information from the same familiar search box. The company was founded by former executives from Google and YouTube. Learn more and start searching today at neeva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230213005065/en/
Contact information
Contact details
press@neeva.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom